The UK and US have hammered out a landmark bilateral deal that will keep no tariffs on British medicine shipments entering the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to increase spending on drugs through the National Health Service (NHS). This move guarantees that duties on these vital products will be held at zero for a period of the next three years.
This agreement follows earlier warnings to significantly raise tariffs on branded drug imports, with increases discussed up to 100%.
"This deal with the UK strengthens the international landscape for cutting-edge drugs and introduces much-needed fairness to American-British pharmaceutical trade," a statement noted.
Economic Impact
Pharmaceuticals are one of the Britain's most significant goods shipped to the US, which is clearly the largest buyer for large companies like GSK and AstraZeneca.
Statistics reveal that in the year prior to September, the UK shipped medicines valued at billions to the US. This figure made up 17.4% of British export trade in that span.
"This guarantee safeguards jobs, boosts funding and sets the stage for the UK to emerge as a international leader for medical research," a government official remarked.
Detailed British Pledges
The pact includes several key commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it deems new treatments to be too expensive by 25%.
- Boosted Medicine Funding: There is a goal to raise overall health service expenditure on medicines from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The amount drug companies must pay back to the NHS to prevent overspending will be capped at 15%. Last year, repayments were more than 20%.
Recent Tensions
This agreement takes place against a long-running row between the sector and the British authorities over medicine costs and approval rates.
These tensions were intensified by arguments that US patients were charged significantly more for the identical medicines than people in the Britain and the EU.
Over the last 18 months, several significant manufacturing plans in the UK have been paused or scrapped, while substantial investments have been directed toward projects in the United States.
The Science Minister publicly accepted that the NHS must spend more on drugs, noting that its spending on drugs had shrunk as a percentage of its resources over the last ten years.
